Adulteration vs Misbranding
Adulteration (FFDCA §402) vs misbranding (FFDCA §403) are the two distinct FDA enforcement pathways for dietary supplements. Adulteration covers product-side failures — contamination, unsanitary conditions, non-conforming composition, unsafe new dietary ingredient, significant-or-unreasonable risk. Misbranding covers label-side failures — false or misleading statement, missing required information, mis-declared identity, mis-declared net weight, disease claim without approval. Both are prohibited acts under §301 with seizure, injunction, and warning-letter authority. Remediation pathway is different: adulteration typically requires recall + manufacturing remediation; misbranding may be addressed via label correction alone. Brand and CM must correctly classify the failure to scope the response.
01What the two pathways cover
FFDCA divides supplement-side failures into two distinct prohibited-act categories. Adulteration (§402) means the product itself fails to meet safety, sanitation, identity, strength, purity, or quality standards. Misbranding (§403) means the label or labelling is false, misleading, or fails to provide required information. Both are §301 prohibited acts; both empower FDA to seize, enjoin, issue Warning Letters, refer for criminal prosecution. But they invoke different root causes and require different remediation.
02Adulteration categories under §402
FFDCA §402(a) through (g) and §402(f) for supplements specifically enumerate adulteration grounds:
| §402 subsection | Adulteration ground | Typical supplement scenario |
|---|---|---|
| §402(a)(1) | Poisonous or deleterious substance that may render the product injurious to health | Heavy metal contamination above safe-use threshold; melamine contamination |
| §402(a)(2)(B) | Class II/III added substance unsafe under §409 | Unapproved food additive present at material level |
| §402(a)(3) | Filthy, putrid, decomposed | Rodent / insect contamination; bacterial decomposition |
| §402(a)(4) | Prepared, packed, or held under unsanitary conditions | Facility cGMP failure under Part 111 |
| §402(b) | Inferior — added or removed substance to mask quality, substituted in whole or part, damage concealed | Marker-spiked botanical extract; substituted lower-quality ingredient |
| §402(f)(1)(A) | Dietary supplement presents significant or unreasonable risk of illness or injury | Pure / highly concentrated caffeine sold direct-to-consumer; ephedra (pre-ban) |
| §402(f)(1)(B) | New dietary ingredient with no history of safe use | NDI not notified under §413 or notified without adequate safety basis |
| §402(g) | Manufactured in violation of Part 111 cGMP | Most common — any §111 non-compliance produces deemed-adulteration |
03Misbranding categories under §403
| §403 subsection | Misbranding ground | Typical supplement scenario |
|---|---|---|
| §403(a)(1) | Labelling false or misleading in any particular | False ingredient claim; mis-stated potency; non-existent certification |
| §403(e) | Lacking name and place of business of manufacturer / packer / distributor | Missing or incomplete responsible-party address |
| §403(f) | Required information not prominent / conspicuous | Supplement Facts panel illegible; warning hidden |
| §403(g) | Standard of identity not met (where applicable) | Limited application to supplements; mostly food-side |
| §403(i) | Identity / quantity not declared | Missing common name; missing net weight |
| §403(q) | Nutrition labelling not as required (per §101.36 for supplements) | Supplement Facts panel mis-formatted; missing required nutrient declaration |
| §403(r)(1)(A) | Nutrient-content claim not authorised | Unauthorised nutrient claim (e.g. 'high in' without meeting threshold) |
| §403(r)(1)(B) | Health claim not authorised | Unapproved disease-treatment / -prevention claim |
| §403(r)(6) | Structure/function claim without §101.93 notification and disclaimer | S/F claim made without 30-day notification + missing FDA disclaimer |
| §403(s)(1)–(2) | Supplement-specific identity not declared | Not labelled as 'dietary supplement'; statement of identity missing |
| §403(w) | Major food allergen not declared per FALCPA | Undeclared milk / soy / egg / peanut / tree nut / wheat / fish / shellfish / sesame |
| §403(y) | Domestic address or phone for serious AE reporting not declared | Missing AE-reporting contact (DSNDCPA requirement) |
04Failures that are BOTH adulteration and misbranding
Some common supplement failures fall under both prohibited-act categories — and FDA Warning Letters typically cite both:
- Undeclared allergen — adulterated under §402(a)(1) (injurious to health for sensitised consumer) AND misbranded under §403(w) (FALCPA declaration missing).
- Mis-stated potency — adulterated under §402(b) (composition substituted) AND misbranded under §403(a)(1) (false labelling).
- Wrong-species botanical — adulterated under §402(b) (substituted) AND misbranded under §403(a)(1) (false ingredient).
- Disease-treatment claim — misbranded under §403(r)(1)(B) AND the product may be deemed an unapproved new drug under §201(g)(1)(B), invoking §505 enforcement.
- Pure caffeine D2C — adulterated under §402(f)(1)(A) (significant risk) AND typically misbranded under §403(a)(1) (false safe-use representation).
- Adulterated NDI — adulterated under §402(f)(1)(B) (no history of safe use, no NDIN) AND misbranded under §403(a)(1).
05Enforcement consequences and remediation
| FDA tool | Adulteration | Misbranding | Both |
|---|---|---|---|
| Warning Letter (§309) | Yes | Yes | Most common — usually cites both |
| Seizure (§304) | Yes | Yes | Yes |
| Injunction (§302) | Yes | Yes | Yes |
| Criminal prosecution (§303) | Yes (strict liability for officers) | Yes (strict liability for officers) | Yes |
| Import refusal (§801) | Yes (Detention Without Physical Examination) | Yes | Yes |
| Reportable Food Registry | Yes (Class I/II hazard) | Limited (only when also adulterated) | Yes |
Remediation pathway differs:
- Adulteration — typically requires recall + production stoppage + Part 111 investigation + CAPA + verification testing. Restoration of release authority requires evidence of remediation efficacy.
- Misbranding — may be addressable via label correction alone if no product-quality issue (e.g. mis-formatted Supplement Facts). Larger misbranding events still require recall (e.g. undeclared allergen).
- Both — full Part 111 + labelling investigation; recall scope depends on hazard and exposure.
06How V5 Ultimate handles adulteration vs misbranding classification
- Event classification at intake: every deviation / OOS / complaint / label-error / allergen-cross-contact event tagged with primary failure category (adulteration / misbranding / both) + specific §402 or §403 subsection.
- Remediation workflow routing: adulteration events route to Part 111 investigation + CAPA + recall-pre-flight workflow; misbranding-only events route to label-correction + change-control workflow. Both-category events route to combined workflow.
- Recall pre-flight: V5 forward-models distribution exposure; if event is adulteration or includes adulteration component, recall scope generated from genealogy + distribution records.
- Reportable Food Registry integration: Class I/II adulteration events auto-stage RFR submission package per 21 U.S.C. §350f.
- FFDCA citation in regulatory reports: per-event regulatory-reporting pack cites the specific §402 / §403 subsection violated; reduces back-and-forth with FDA during inspection / investigation response.
- Misbranding-only label-correction fast track: when failure is misbranding-only and no product-quality issue exists, V5 routes to label change-control with abbreviated review (still e-sig + reviewer); does not engage the full cGMP investigation track unnecessarily.
- Allergen-cross-contact dual workflow: undeclared-allergen event auto-tagged as BOTH adulteration AND misbranding; engages both workflows in parallel; recall pre-flight prioritised.
- Inspection-response template library: per-FFDCA-section template responses for 483 / Warning Letter; reduces drafting time when responding to FDA citations.
- Senior officer notification: criminal-liability events (recurring or willful adulteration / misbranding) auto-escalate to officer-level notification given §303 strict-liability exposure to corporate officers.
Frequently asked questions
Q.Is undeclared allergen adulteration or misbranding?+
Both. §402(a)(1) for the safety risk to sensitised consumers, AND §403(w) for the FALCPA declaration failure. FDA Warning Letters typically cite both.
Q.Can a label-correction-only remediation resolve a misbranding finding?+
Sometimes — if the misbranding is purely labelling (e.g. mis-formatted Supplement Facts panel) with no product-quality issue, label correction + reprint may suffice. Allergen-related misbranding always requires recall because the safety risk is real.
Q.Is §402(g) cGMP adulteration automatic on any Part 111 finding?+
Yes — the regulation is explicit: any product manufactured in violation of Part 111 is deemed adulterated under §402(g). FDA does not need to prove the product is actually unsafe; the cGMP violation is sufficient.
Q.Can structure/function claim violations be adulteration?+
Generally no — S/F claim violations are §403(r)(6) misbranding, not adulteration. However, if the claim crosses into disease-treatment territory, the product may be deemed an unapproved new drug under §201(g)(1)(B), invoking §505 enforcement (a separate and more serious pathway).
Q.Does criminal liability really attach to corporate officers?+
Yes — §303 imposes strict criminal liability on responsible corporate officers (Park doctrine, 421 U.S. 658 (1975)). Officers can be prosecuted for adulteration / misbranding events even without direct knowledge of the violation. Most cases are misdemeanor; willful or repeat violations can be felony.
Q.What is the difference between adulteration and unapproved-new-drug status?+
Adulteration is a safety-or-cGMP failure within the supplement framework. Unapproved-new-drug means the product has crossed the line into drug regulation (typically by making disease claims) and is subject to §505 — which is a much more serious enforcement pathway with pre-market approval requirements.
Q.Can adulteration trigger an import refusal?+
Yes — FDA can place a product on Detention Without Physical Examination (DWPE / Import Alert) for adulteration or misbranding, requiring the importer to demonstrate compliance for every shipment before release. Removal from DWPE typically takes 12-24 months of demonstrated compliance.
Primary sources
- FFDCA §402 — Adulterated food and dietary supplements (21 U.S.C. §342)
- FFDCA §403 — Misbranded food and dietary supplements (21 U.S.C. §343)
- FFDCA §301 — Prohibited acts (21 U.S.C. §331)
- FFDCA §304 — Seizure authority (21 U.S.C. §334)
- 21 CFR 111 — Dietary supplement cGMP (failures often produce adulteration)
- 21 CFR 101.36 — Supplement Facts panel (failures often produce misbranding)
Further reading
- 21 CFR Part 111cGMP — most adulteration findings cite Part 111 non-compliance.
- Supplement Facts panelMost misbranding findings cite Supplement Facts errors.
- Structure/function claimClaim violations are misbranding under §403(r).
- cGMP Warning Letter (supplement)Warning Letter is the primary delivery vehicle for both pathways.
- Allergen statement & cross-contactUndeclared allergen is BOTH adulteration AND misbranding.
V5 Ultimate ships with the Adulteration vs Misbranding controls already wired in — audit trail, e-signatures, validation evidence. Free trial, no credit card, onboard in days, not months.